Plug and Play is on the hunt for real estate for its Houston office. Photo by Zview/Getty Images

Another accelerator with a global presence is itching to get into the Houston innovation ecosystem. California-based Plug and Play will launch its Houston accelerator program sometime in the fourth quarter of this year and is currently looking for the right location to house the company's local operations.

The organization, which has 30 locations all over the world and has made early stage investments in the likes of DropBox, PayPal, Lending Club, is hosting a series of events on June 4 to 6 at the TMC Innovation Institute. The events are free and open to the public.

"Our goal is to introduce innovation trends and disruptive technologies from Plug and Play's global ecosystem to leading corporations in Texas focused on energy, sustainability, and health care," says Omer Gozen, vice president of Plug and Play's New Materials, Food, and Sustainability Programs, in an email. "This event allows us to bring the very-best startups to Houston's backyard."

The Plug and Play programming's intent is twofold. While the talks and pitches will spark conversations within Houston's ecosystem, it will also give the organization a chance to meet face to face with Houston corporations and startups, says a spokesperson. And Houston's huge corporate presence is a major draw, says Susan Davenport, senior vice president of economic development for the Greater Houston Partnership, in a statement.

"With our large concentration of Fortune 500 companies and a broad diversity of industry, Houston is an ideal location for a platform like Plug and Play that connects startups with major corporations," says Davenport.

The city has been communicating with Plug and Play for a while and has "worked closely" with them on this new office. Representatives from the GHP and Mayor Sylvester Turner even visited Plug and Play's headquarters last year.

"Their announcement is further evidence of the growing momentum behind Houston's startup and innovation ecosystem—one that has seen the emergence of a series of accelerators and major investments in technology in less than two years," Davenport says in the statement. "That Houston is one of only a handful of locations for Plug and Play in North America indicates how important this region is to the relationship between emerging businesses and major companies."

The accelerator will run for three months twice a year with 20 startups in each cohort. The cohorts are stage-agnostic and do not require any equity or fees for the startups to participate.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”